Member Info for YamR1man

WOW ! You can say that again....er, ok, I will, WOW!

Well housebuilder, the sp carries on up after the dividend. What did you decide to do pre dividend? Hopefully it was the right one for you. So far, I made the best one for me and collected the divi. Have you bought in yet.?

And a tiny bit more...
Woohooo, get in

Very frustrating here. No sustainable progress at all. I still believe it's a good long term bet.... but it's gonna be over a couple of years. Patience will prevail. LOL. Well, all that sounded positive didn't it but still p!$$£d off. Have fun folks

Blah,blah, blah.
Anyway, whilst always interesting to hear Tommymech's point of view of the way this industry works...this RNS is just as has been mentioned ie,...nothing new. We all know how the planet must be protected and what needs to happen. BTW, the jury is still out on what and how the best way forward is. Complicated enough without the problem how some countries couldn't care less.
This RNS just seems like a generic report again. Sorry, I'm impatient but past decades of progress give me reason. Of course, fantastic news 'could ' be imminent and my frame of mind will instantly change. C'est la vie

Wow, very unusual day trend. So stable? Interesting.

We'll see what the US thinks of the CMA news soon.
My daughters will only be interested in JD at my wake..LOL

Ref the footlocker news....the market doesn't appear to see the CMA opinion as bad news......today at least. Obviously, reading the JD RNS ... JD are still all for the T/O despite the mention of increasing DTC by Nike, etc. The consumer will decide via the price and website they can buy the shoes at cheapest...don't you think?
BTW, the company's future sp and the history of share splits is and was the attraction for me. If COVID hadn't happened then the sp could have been 20% higher.....maybe, LOL. C'est la vie

...which we want to believe don't we. Obviously, if it was a negative then we wouldn't want to....LOL. Seriously, it seems to be STILL going from strength to strength. Yippee

....Has held up well and hasn't fell by more than the dividend so it's a up day for me .. YAY ! Onwards and..etc

Yep, you could be right.... we'll soon know. Obviously, I'm hoping it won't be drastic and also hope sp carries on up. It's a casino but a very good company

House...if anyone knows the answer to your question then they have a working crystal ball and will be able to win the next lottery ..LOL. Can't see it dropping to £30.....maybe £34 but nobody knows until tomorrow. Good luck to everyone is the only positive I can give. Have fun

Taver... hope you're not thinking of selling now that it's reached your target? Only going to get better....as long as there's no further lockdowns.

Housebuilder... I waited to buy in until the last ex div date had passed and thought I'd bought well. In hindsight, of course, it was a mistake because this sp is still climbing and I missed the last dividend. Happy to hold now and collect the next big one. It's all a gamble of course. Good luck to everyone here.

A grand total of 3 trades today !!?

Why isn't this board buzzing with congratulations for holders? I appreciate nobody like to boast but....!
Anyway , congratulations to all investors. Unfortunately, I not one you. DOH ! LOL

AstraZeneca eyes big jump in revenue after Alexion acquisition
In the first half of the year, the COVID-19 vaccine delivered sales twice the consensus view

AstraZeneca PLC - AstraZeneca eyes big jump in revenue after Alexion acquisition
AstraZeneca PLC (LSE:AZN) has announced higher full-year guidance to include the newly acquired Alexion, after the transaction was completed last week.

The pharma giant expects total revenue to jump 21-22%, with core earnings per share (EPS) from US$5.05 to US$5.40.

READ: AstraZeneca says Alexion receives recommendation to use rare blood disorder drug in kids
The forecast doesn’t include revenue or profit impact from sales of the pandemic COVID-19 vaccine, as the effects of the pandemic remain uncertain.

In the half year ended 30 June, revenue climbed 31% to US$8.2bn, with core EPS up 26% to US$2.53 per share.

New medicines were up 31%, oncology advanced 19% while respiratory and immunology increased by 11%.

The COVID-19 vaccine generated US$894mln of sales, twice the consensus view of US$422mln.

The jab was beneficial in lifting performance in the emerging markets segment, where sales were up 26%, with Europe and the US up 33% and 16% respectively.

Profit before tax came in at US$2.3bn from US$1.8bn last year.

Analysts at Shore Capital said this was “a steady quarter” and broker forecasts will need to be updated based on the Alexion addition.

I assume it's because of the DraftKings results and thereby Flutter that has affected us? Not sure why tho.....you'd imagine that is a good sign that our results will be equally positive or better? We'll soon see next Thursday. Do I need to cross my fingers or not? Hmmm....

..that was a day of two halves ! Great morning....bad afternoon?

Now what's happened?